'Maximising off patent medicines and why the PBS needs a biosimilar strategy'

Chad Rieger, Head of Medical Affairs and Policy for Australia and New Zealand at Sandoz, argues that Australia needs a deliberate national biosimilar strategy, starting with lower patient copayments, so savings from off-patent biologics can fund broader access and the next generation of medicines. …